Panitumumab-Induced Periorbital Dermatitis: A Case Report

Clin Cosmet Investig Dermatol. 2024 Apr 3;17:763-767. doi: 10.2147/CCID.S459067. eCollection 2024.ABSTRACTPanitumumab is a recombinant, fully humanized immunoglobulin G2 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is approved for the first- and second-line treatment of advanced wild-type KRAS colorectal cancer. Although common cutaneous side effects include acneiform dermatitis, folliculitis, and xerosis, ocular toxicities have occasionally been reported. Herein, we report the case of an 81-year-old Thai female with chemorefractory advanced stage sigmoid colon cancer who developed isolated periorbital dermatitis following treatment with panitumumab plus modified FOLFOX6. The cutaneous adverse reaction recurred after subsequent infusions; however, it was alleviated by topical therapy. To our knowledge, panitumumab-induced periorbital dermatitis is exceptionally rare. To raise awareness of potential periocular cutaneous side effects in patients taking EGFR inhibitors, the published literature regarding periorbital dermatitis induced by these agents has also been reviewed in this article. Periorbital dermatitis should be considered as a potential cutaneous reaction following panitumumab administration, and should be promptly treated.PMID:38586180 | PMC:PMC10999196 | DOI:10.2147/CCID.S459067
Source: Clinical, Cosmetic and Investigational Dermatology - Category: Dermatology Authors: Source Type: research